Abstract
The signal transducer and activator of transcription, STAT5b, has been implicated in signal transduction pathways for a number of cytokines and growth factors, including growth hormone (GH). Pulsatile but not continuous GH exposure activates liver STAT5b by tyrosine phosphorylation, leading to dimerization, nuclear translocation, and transcriptional activation of the STAT, which is proposed to play a key role in regulating the sexual dimorphism of liver gene expression induced by pulsatile plasma GH. We have evaluated the importance of STAT5b for the physiological effects of GH pulses using a mouse gene knockout model. STAT5b gene disruption led to a major loss of multiple, sexually differentiated responses associated with the sexually dimorphic pattern of pituitary GH secretion. Male-characteristic body growth rates and male-specific liver gene expression were decreased to wild-type female levels in STAT5b −/− males, while female-predominant liver gene products were increased to a level intermediate between wild-type male and female levels. Although these responses are similar to those observed in GH-deficient Little mice, STAT5b −/− mice are not GH-deficient, suggesting that they may be GH pulse-resistant. Indeed, the dwarfism, elevated plasma GH, low plasma insulin-like growth factor I, and development of obesity seen in STAT5b −/− mice are all characteristics of Laron-type dwarfism, a human GH-resistance disease generally associated with a defective GH receptor. The requirement of STAT5b to maintain sexual dimorphism of body growth rates and liver gene expression suggests that STAT5b may be the major, if not the sole, STAT protein that mediates the sexually dimorphic effects of GH pulses in liver and perhaps other target tissues. STAT5b thus has unique physiological functions for which, surprisingly, the highly homologous STAT5a is unable to substitute.
References
54
Referenced
776
10.1146/annurev.ph.47.030185.002411
10.1146/annurev.ph.58.030196.001155
10.1016/0092-8674(84)90030-8
10.1016/B978-0-12-571148-7.50009-9
10.1016/S0021-9258(18)66653-0
10.1016/0960-0760(92)90332-D
10.1016/0960-0760(92)90333-E
10.1073/pnas.88.15.6868
10.1677/joe.0.1310395
10.1074/jbc.270.22.13262
10.1074/jbc.271.10.5929
10.1210/mend.11.4.9904
10.1074/jbc.270.50.29998
10.1016/S0021-9258(18)42011-X
10.1002/j.1460-2075.1994.tb06495.x
10.1002/j.1460-2075.1994.tb06756.x
10.1002/j.1460-2075.1995.tb07100.x
10.1002/j.1460-2075.1995.tb07126.x
10.1073/pnas.92.19.8831
10.1016/1074-7613(95)90140-X
- M Dajee, A V Kazansky, B Raught, G M Hocke, G H Fey, J S Richards Mol Endocrinol 10, 171–184 (1996). / Mol Endocrinol by Dajee M (1996)
- C M Silva, H Lu, R N Day Mol Endocrinol 10, 508–518 (1996). / Mol Endocrinol by Silva C M (1996)
- L S Smit, D J Meyer, N Billestrup, G Norstedt, J Schwartz, C Carter-Su Mol Endocrinol 10, 519–533 (1996). / Mol Endocrinol by Smit L S (1996)
10.1073/pnas.92.12.5482
10.1073/pnas.92.10.4215
10.1074/jbc.270.40.23254
10.1002/j.1460-2075.1995.tb07192.x
10.1038/382174a0
10.1038/382171a0
10.1038/380627a0
10.1038/380630a0
10.1016/S0092-8674(00)81289-1
10.1016/S0092-8674(00)81288-X
10.1101/gad.11.2.179
- G B Udy, M J Evans BioTechniques 17, 887–894 (1994). / BioTechniques by Udy G B (1994)
- D J Waxman, D P Lapenson, S S Park, C Attisano, H V Gelboin Mol Pharmacol 32, 615–624 (1987). / Mol Pharmacol by Waxman D J (1987)
10.1016/0076-6879(91)06115-J
10.1016/0960-0760(93)90053-Y
10.1677/joe.0.1470507
10.1038/314281a0
10.1530/acta.0.1240283
10.1073/pnas.82.9.2579
10.1016/0076-6879(91)06096-L
10.1016/0092-8674(82)90440-8
- A M Gronowski, Z Zhong, Z Wen, M J Thomas, J E Darnell, P Rotwein Mol Endocrinol 9, 171–177 (1995). / Mol Endocrinol by Gronowski A M (1995)
10.1016/S0021-9258(17)37132-6
10.1074/jbc.271.47.29978
10.1128/MCB.15.9.4672
- Z Laron Curr Opin Pediatr 5, 474–480 (1993). / Curr Opin Pediatr by Laron Z (1993)
- M C Postel-Vinay Rev Prat 44, 1281–1285 (1994). / Rev Prat by Postel-Vinay M C (1994)
- Z Laron, B Klinger, R Eshet, H Kaneti, A Karasik, A Silbergeld Isr J Med Sci 29, 757–763 (1993). / Isr J Med Sci by Laron Z (1993)
10.1016/S0021-9258(19)50612-3
10.1006/geno.1995.1235
10.1016/S0092-8674(00)81286-6
Dates
Type | When |
---|---|
Created | 23 years, 1 month ago (July 26, 2002, 10:42 a.m.) |
Deposited | 3 years, 4 months ago (April 13, 2022, 3:28 p.m.) |
Indexed | 2 days, 18 hours ago (Aug. 29, 2025, 6:48 a.m.) |
Issued | 28 years, 1 month ago (July 8, 1997) |
Published | 28 years, 1 month ago (July 8, 1997) |
Published Online | 28 years, 1 month ago (July 8, 1997) |
Published Print | 28 years, 1 month ago (July 8, 1997) |
@article{Udy_1997, title={Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression}, volume={94}, ISSN={1091-6490}, url={http://dx.doi.org/10.1073/pnas.94.14.7239}, DOI={10.1073/pnas.94.14.7239}, number={14}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Udy, Garry B. and Towers, Raewyn P. and Snell, Russell G. and Wilkins, Richard J. and Park, Soo-Hee and Ram, Prabha A. and Waxman, David J. and Davey, Helen W.}, year={1997}, month=jul, pages={7239–7244} }